Trial Profile

A phase I, randomized, open-label, active-controlled, three-way treatment trial assessing pharmacokinetics, bioavailability and safety of two single doses of CAM2038 (Buprenorphine FluidCrystal(R) Injection Depot) q4w (once monthly) and four repeat doses of CAM2038 q1w (once weekly) versus active comparators, intravenous and sublingual buprenorphine, in healthy volunteers under naltrexone blockage

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Mar 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Jan 2017 Results published in the Advances in Therapy.
02 Aug 2014 New trial record
29 Jul 2014 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com